EcoDrugPlus

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSACIG00000003899
Gene Symbol: CACNA1FB
1 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, B

Ensembl ID : ENSACIG00000022926
Gene Symbol: CACNA1SB
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSACIG00000018764
Gene Symbol: CACNA1AB
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1a

Ensembl ID : ENSACIG00000003681
Gene Symbol: CACNA2D1A
1 Cross references
230 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSACIG00000009519
Gene Symbol: CACNA2D2A
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSACIG00000008990
Gene Symbol: CACNB1
1 Cross references
210 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 2a

Ensembl ID : ENSACIG00000016610
Gene Symbol: CACNB2A
1 Cross references
204 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSACIG00000000023
Gene Symbol: CACNB3A
1 Cross references
203 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 1a

Ensembl ID : ENSACIG00000006371
Gene Symbol: CACNG1A
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSACIG00000005590
Gene Symbol: CACNG4B
1 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5a

Ensembl ID : ENSACIG00000006340
Gene Symbol: CACNG5A
1 Cross references
184 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6a

Ensembl ID : ENSACIG00000003478
Gene Symbol: CACNG6A
1 Cross references
181 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).